RA TV: Past, present, & future
In this month’s episode of RA TV, we look back at the past year for biotech, examine today’s headlines, and contemplate the future of this pandemic — and maybe the next one.
And now for something completely different
LENZ Therapeutics CEO Eef Schimmelpennink spoke with RApport about how last year’s acquisition of Pfenex by Ligand gave him a chance to seek out a new challenge, the benefits of breaking the mold, and helping 120 million Americans ditch their reading glasses.
RA TV: Aduhelm & Patient-Centered Healthcare Reforms
Listen in as RA Capital’s TechAtlas Associates convene to discuss recent Covid-19 news. Learn about the emerging Delta variant, new data from Novavax and CureVac, and the potential association between mRNA vaccines and myocarditis.
Accelerating life science tools R&D with venture studios
Interest in life science technologies and tools is accelerating with the advent of CRISPR and other aspects of synthetic biology. The ability to have a capital efficient way to advance these innovations is very attractive and will help drive innovation.
RA TV: Vaccines versus variants
Listen in as RA Capital’s TechAtlas Associates convene to discuss recent Covid-19 news. Learn about the emerging Delta variant, new data from Novavax and CureVac, and the potential association between mRNA vaccines and myocarditis.
It’s time to bring generic drug manufacturing back to the U.S.
Repatriating the American drug supply is key not just to averting shortages but to restoring and preserving the integrity of generic drugs in America.